IRVINE, CA -- (Marketwire) -- 07/25/12 -- BIOLASE, Inc. (NASDAQ: BIOL), the world's leading dental laser manufacturer and distributor, today announced that it has completed its initial build-out of the inside sales organization at its corporate headquarters based in Irvine, California. This group is currently made up of 5 inside sales representatives and lead generators, who work in partnership with the direct sales team to maximize sales, leverage the existing installed customer base, and drive smaller deals to closure. BIOLASE plans to grow the group to between 8 and 10 by the end of the year.
The inside sales group will build a rapport with customers to understand their needs and develop opportunities, ensure higher customer satisfaction and engage customers to provide validation of the business impact of the complete line of BIOLASE product offerings, specifically the iLase and newly introduced EPIC 10, the first of the newly introduced EPIC line of diode laser systems, refurbished, certified pre-owned Waterlase MD Turbo laser systems, and lower priced BIOLASE DaVinci Imaging products, as well as warranties and service contracts.
The team of lead generators will develop relationships with prospective clients until they are ready to be turned over to the direct sales team.
Chairman and CEO Federico Pignatelli said, "BIOLASE has the largest installed base of laser equipment in dentistry by a large margin with approximately 20,000 units, and establishing an efficient and active inside sales group is a good way to leverage our vast customer community. In addition, our goal is to become the top provider of technology solutions and to maintain that position as a true multi-product, multi-platform corporation. In order to achieve that goal, we have created a 'high touch' environment in which our interaction with customers is frequent so that they feel well supported and are provided information on the newest products and opportunities to build their dental practice through the use of our best-in-class BIOLASE technologies.
"We want to ensure that the sales cycle doesn't stop after the initial sale is made and that clients remain happy and loyal customers," added Pignatelli. "We believe this group will make signification contributions in the second half of the year."
About BIOLASE, Inc.
BIOLASE, Inc., the World's leading Dental Laser Company, is a medical technology company that develops, manufactures and markets dental lasers and also distributes and markets dental imaging equipment; products that are focused on technologies that advance the practice of dentistry and medicine. The Company's laser products incorporate approximately 285 patented and patent pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. Its imaging products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold more than 19,600 lasers among 16,000 customers. Other products under development address ophthalmology and other medical and consumer markets.
This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.
For further information, please contact:
of Allen & Caron